Cancer vaccine trial for rare skin cancer halted before starting
NCT ID NCT05799612
First seen Feb 19, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study was designed to test a new mRNA vaccine for a rare skin cancer called cutaneous angiosarcoma. The goal was to find the highest safe dose and check for side effects. However, the study was withdrawn before any patients were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.